As Associate Director, Data & Information Architecture, you’ll be responsible for designing and executing the enterprise data architecture strategy that enables REGENXBIO’s commercial growth. Working closely with business & IT leadership, you’ll build and lead a secure, scalable commercial data warehouse; integrate internal and third-party data; establish master and reference data standards; and partner across Commercial, Medical, Legal, and IT to deliver trusted analytics with clear lineage, quality, and privacy controls. This is a “build and scale” role focused on enabling growth: ensuring systems and data support the next phase of the business.
We set our employees up for success. To be successful in this role and help us achieve our goals, we are looking for someone with the following skills and qualifications:
By joining REGENXBIO, you'll have the opportunity to be part of a growing company with an incredible team that is passionate about developing novel AAV gene therapies for patients in need.
We offer a comprehensive and competitive benefit & compensation package which includes market-competitive salaries, an annual bonus program, education assistance, retirement plan with employer match, stock options at all levels, summer hours and more! Additionally, professional development is important to us. By joining our team, you’ll have the opportunity to be exposed to challenging projects and have access to development resources to help you grow personally and professionally.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO’s AAV Therapeutic platform, including Novartis’ ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.